1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Top-Line Results From Third Phase III Study

 
• By John Davis

Pfizer’s next-generation JAK1 inhibitor, abrocitinib, continues to show beneficial effects in atopic dermatitis (eczema), in the JADE COMPARE study, comparable to the positive control dupilumab and, in the case of itch, with a faster onset at the higher dose.  

Starting_Blocks
• Source: Shutterstock

Pfizer Inc.’s next-generation oral JAK1 inhibitor, abrocitinib, is likely to be a strong competitor to Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for treating atopic dermatitis, judging by top-line results from a third Phase III study which showed a higher dose of abrocitinb was significantly superior to the interleukin-4/IL-13 inhibitor, dupilumab, in reducing itch after the first two weeks of therapy.

Having a quicker effect on symptoms could be an important differentiator for abrocitinib in its likely marketing battle with the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.